Personalizing the Intensity of Blood Pressure Control: Modeling the Heterogeneity of Risks and Benefits From SPRINT (Systolic Blood Pressure Intervention Trial)
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background—: In SPRINT (Systolic Blood Pressure Intervention Trial), patients with hypertension and high cardiovascular risk treated with intensive blood pressure (BP) control (<120 mm Hg) had fewer major adverse cardiovascular events (MACE) and deaths but higher rates of treatment-related serious adverse events (SAE) than patients randomized to standard BP control (<140 mm Hg). However, the degree of benefit or harm for an individual patient could vary because of heterogeneity in treatment effect. Methods and Results—: Using patient-level data from 9361 randomized patients in SPRINT, we developed models to predict risk for MACE or death and treatment-related SAE to allow for individualized BP treatment goals based on each patient’s projected risk and benefit of intensive versus standard BP control. Models were internally validated using bootstrap resampling and externally validated on 4741 patients from the ACCORD-BP (The Action to Control Cardiovascular Risk in Diabetes blood pressure) trial. Among 9361 SPRINT patients, 755 patients (8.1%) had a MACE or death event and 338 patients (3.6%) had a treatment-related SAE during a median follow-up of 3.3 years. The MACE/death and the SAE model had C statistics of 0.72 and 0.70, respectively, in the derivation cohort and 0.69 and 0.65 in ACCORD. The MACE/death model had 10 variables including treatment interactions with age, baseline systolic BP, and diastolic BP, and the SAE model had 8 variables including treatment interaction with number of BP medications. Intensive BP treatment was associated with a mean 2.2±2.6% lower risk of MACE/death compared with standard treatment (range, 20.7% lower risk to 19.6% greater risk among individual patients) and a mean 2.2±1.2% higher risk for SAEs (range, 0.5%–15.8% more harm in individual patients). Conclusions—: To translate the findings from SPRINT to clinical practice, we developed prediction models to tailor the intensity of BP control based on the projected risk and benefit for each unique patient. This approach should be prospectively tested to better engage patients in shared medical decision making and to improve outcomes. Clinical Trial Registration—: URL: https://clinicaltrials.gov . Unique identifier: NCT01206062.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598 · cited 1×
“External Validation Both the risk models were externally validated within the BP arm of the ACCORD (The Action to Control Cardiovascular Risk in Diabetes) trial, conducted from January 2003 through June 2009.(9) The trial enrolled 4741 patients with diabetes mellitus at high cardiovascular risk, randomized to receive…”
MethodClinical Prediction Models: A Practical Approach to Development, Validation, and Updating
Steyerberg, E. W. (2019) · Statistics for Biology and Health · doi:10.1007/978-3-030-16399-0 · Cited by 3,281
Internal validation of predictive models
Steyerberg, E. W., Harrell, F. E., Borsboom, G. J. J. M., Eijkemans, M. J. C., Vergouwe, Y., & Habbema, J. D. F. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00341-9 · Cited by 2,746
Scientific evidence underlying the ACC/AHA clinical practice guidelines.
Tricoci, P. (2009) · JAMA · doi:10.1001/jama.2009.205 · Cited by 908 · cited 1×
“Although guidelines and performance measures have been the primary strategies, these have failed to insure that the Institute of Medicine’s goals for effective, safe, patient-centered care have been achieved.(12,13) An important and underused strategy to accelerate the translation of clinical trials to practice is to…”
BackgroundAssessing and reporting heterogeneity in treatment effects in clinical trials: a proposal
Kent, D. M., Rothwell, P. M., Ioannidis, J. P., Altman, D. G., & Hayward, R. A. (2010) · Trials · doi:10.1186/1745-6215-11-85 · Cited by 504
Cited by
Recommendations for Reporting Machine Learning Analyses in Clinical Research
Stevens, L. M., Mortazavi, B. J., Deo, R. C., Curtis, L., & Kao, D. P. (2020) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.120.006556 · Cited by 268
“25,26 In such cases, additional ML and statistical approaches such as traditional regression or survival methods, double ML, 21 and causal inference techniques 27,28 may be used in conjunction with or may be considered over unsupervised approaches.”
Basu, S., Sussman, J. B., Rigdon, J., Steimle, L., Denton, B. T., & Hayward, R. A. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002410 · Cited by 77
Buckley, L. F., Dixon, D. L., Wohlford, G. F., Wijesinghe, D. S., Baker, W. L., & Van Tassell, B. W. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13248 · Cited by 42
Metadata
- Authors
- Patel, K. K., Arnold, S. V., Chan, P. S., Tang, Y., Pokharel, Y., Jones, P. G., & Spertus, J. A.
- Venue
- Circulation: Cardiovascular Quality and Outcomes
- Published
- 2017-04
- Volume
- 10
- Issue
- 4
- ISSN
- 1941-7705 (ISSN-L)
- 1941-7713
- OpenAlex
- W2988401315
- Cited by
- 43
- References
- 5
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Personalizing the Intensity of Blood Pressure Control: Modeling the Heterogeneity of Risks and Benefits From SPRINT (Systolic Blood Pressure Intervention Trial). https://app.cochat.ai/papers/10.1161/circoutcomes.117.003624
- The paper
- Patel, K. K., Arnold, S. V., Chan, P. S., Tang, Y., Pokharel, Y., Jones, P. G., & Spertus, J. A. (2017). Personalizing the Intensity of Blood Pressure Control: Modeling the Heterogeneity of Risks and Benefits From SPRINT (Systolic Blood Pressure Intervention Trial). Circulation: Cardiovascular Quality and Outcomes. https://doi.org/10.1161/circoutcomes.117.003624
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.